$FLNA News

Filana Therapeutics Announces Fifth Circuit Rules Texas District Court Misapplied Legal Standard In Class Certification

Filana Therapeutics to Participate in the 2026 Maxim Growth Summit

Positive FDA Decision Propels Rebranded Filana Therapeutics Epilepsy Research Forward

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

Filana Therapeutics shares are trading higher after the company announced that the FDA lifted the clinical hold on its investigational new drug application, enabling Filana to initiate a planned Phase 2a proof-of-concept study in patients aged 12 to 55 with TSC-related epilepsy.

FDA Lifts Clinical Hold Form Filana Therapeutics' Investigational New Drug Application To Initiate Planned Phase 2a Trial In Participants With Tuberous Sclerosis Complex-Related Epilepsy

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

Filana Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate

Maxim Group Reinstates Buy on Filana Therapeutics, Announces $5 Price Target

Filana Therapeutics Reports Q1 2026 Financial Results and Business Update

Filana Therapeutics Q1 EPS $(0.21) Beats $(0.23) Estimate

Filana Therapeutics Presents TSC-Related Epilepsy Program at Eilat XVIII

Filana Therapeutics Announces Publication in Epilepsia of Preclinical Simufilam Data

Filana Therapeutics Announces Publication In Epilepsia Of Preclinical Data Showing Simufilam Attenuated Seizure Progression In Mouse Model Of Severe TSC-Related Epilepsy

Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Cassava Sciences Changes Name To Filana Therapeutics, Ticker To FLNA, Effective March 11

Cassava Sciences Says U.S. DOJ Fraud Section Closes Its Inquiry Into The Company Regarding Allegations Of Research Misconduct

Watching Cassava Sciences; Traders Circulate Co Files New Trademark For "FILANA THERAPEUTICS", Suggesting A Possible Rebrand Or Maybe Something Else Coming

Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease

Cassava Sciences Announces Publication Of Article Phase 3 Randomized Clinical Trials Of Simufilam In Mild-To-Moderate Alzheimer's Disease In Upcoming Issue Of JPAD